Indian Journal of Medical Biochemistry

Register      Login

VOLUME 27 , ISSUE 2 ( May-August, 2023 ) > List of Articles


Effect of Prostate Cancer on Non-protein Nitrogenous Substances

Sanghapriya Pal, Kiran Dahiya, Rajeev Atri, Hemang Kumar, Aman Chauhan, Shweta Gaur

Keywords : Cancer, Creatinine, Chronic kidney disease, Gleason's scoring, Prostate cancer, Prostate-specific antigen, Urea, Uric acid

Citation Information : Pal S, Dahiya K, Atri R, Kumar H, Chauhan A, Gaur S. Effect of Prostate Cancer on Non-protein Nitrogenous Substances. Indian J Med Biochem 2023; 27 (2):28-32.

DOI: 10.5005/jp-journals-10054-0219

License: CC BY-NC 4.0

Published Online: 20-01-2024

Copyright Statement:  Copyright © 2023; The Author(s).


Introduction: Prostate cancer is one of the most common non-cutaneous malignancies in American males. In 2008, it was the sixth leading cause of death from cancer among males. Population-based cancer registries in India show that this has become a growing health concern in many parts of India. There are many interfaces between cancer and chronic kidney disease (CKD). Materials and methods: Serum levels of urea, creatinine, and uric acid of 50 prostate cancer patients were compared with those of 50 healthy controls, at 95% confidence level taking p < 0.05 as significant. The association of urea, creatinine and uric acid levels with staging, Gleason's scoring and serum prostate-specific antigen (PSA) level was analyzed with the help of appropriate statistical analysis. Results: Among the three prominent non-protein nitrogenous (NPN) substances used for renal assessment, the levels of urea and uric acid in serum were found to be statistically significantly raised (p < 0.05) in patients with prostate cancer as compared with healthy controls. The serum levels of creatinine were higher in cases as compared with controls but the difference was not found to be statistically significant (p = 0.088). Only uric acid level (p = 0.01) changed significantly among the stage A through stage D. We did not find the statistical significant correlation between the level of urea (r = –0.05, p = 0.75), creatinine (r = –0.24, p = 0.09) and uric acid (r = –0.05, p = 0.75) with PSA. Conclusion: From our study, it can be concluded that the evaluation of serum levels of urea, creatinine and uric acid may be of utmost diagnostic and prognostic significance in patients with prostate carcinoma.

  1. Ravizzini G, Turkbey B, Kurdziel K, et al. New horizons in prostate cancer imaging. Eur J Radiol 2009;70(2):212–226. DOI: 10.1016/j.ejrad.2008.09.019.
  2. Jain S, Saxena S, Kumar A. Epidemiology of prostate cancer in India. Meta Gene 2014;2:596–605. DOI: 10.1016/j.mgene.2014.07.007.
  3. Oluboyo AO, Adeleke AT, Oluboyo BO. Evaluation of selected renal markers in prostate cancer. J Appl Sci Environ Manage 2019;23: 1725–1728. DOI: 10.4314/jasem.v23i9.18.
  4. Benli E, Cirakoglu A, Ayyildiz SN, et al. Comparison of serum uric acid levels between prostate cancer patients and a control group. Cent European J Urol 2018;71(2):242–247. DOI: 10.5173/ceju.2018.1619.
  5. Barbosa AI, Castanheira AP, Edwards AD, et al. A lab-in-a-briefcase for rapid prostate specific antigen (PSA) screening from whole blood. Lab Chip 2014;14(16):2918–2928. DOI: 10.1039/c4lc00464g.
  6. Torres da Costa E Silva V, Costalonga EC, Coelho FO, et al. Assessment of kidney function in patients with cancer. Adv Chronic Kidney Dis 2018;25(1):49–56. DOI: 10.1053/j.ackd.2017.10.010.
  7. Fini MA, Elias A, Johnson RJ, et al. Contribution of uric acid to cancer risk, recurrence and mortality. Clin Tranl Med 2012;1:16–30. DOI: 10.1186/2001-1326-1-16.
  8. Scher HI. Benign and malignant diseases of prostate. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, eds. Harrison's Principles of Internal Medicines. 18th ed. New York: McGraw-Hill; 2012. pp. 796–805.
  9. Narayan P. Neoplasms of the prostate gland. In: Tanagho EA, McAninch JW, Eds. Smith's General Urology. 13th ed. London: Prentice-Hall International Inc; 1992. p. 378412.
  10. Fawcett JK, Scott J. A rapid and precise method for the determination of urea. J Clin Pathol 1960;13(2):156–159. DOI: 10.1136/jcp.13.2.156.
  11. Vasiliades J. Reaction of alkaline sodium picrate with creatinine: I. Kinetics and mechanism of formation of the mono-creatinine picric acid complex. Clin Chem 1976;22(10):1664–1671. PMID: 10095.
  12. Prætorius E, Poulsen H. Enzymatic determination of uric acid with detailed directions. Scand J Clin Lab Invest 953;5(3):273–280. DOI: 10.3109/00365515309094197.
  13. Oesterling JE. Prostate-specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145(5):907–923. DOI: 10.1016/s0022-5347(17)38491-4.
  14. White MC, Holman DM, Boehm JE, et al. Age and cancer risk: A potentially modifiable relationship. Am J Prev Med 2014;46(3 Suppl 1):S7–S15. DOI: 10.1016/j.amepre.2013.10.029.
  15. Plackson LA, Pension DF, Vaughan TL, et al. Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol Biomarkers Prev 2003;12:604–609. PMID: 12869398.
  16. Zaitsu M, Takeuchi T, Kobayashi Y, et al. Light to moderate amount of lifetime alcohol consumption and risk of cancer in japan. Cancer 2019;126:1031–1040. DOI: 10.1002/cncr.32590.
  17. Shahinian VB, Bahl A, Niepel D, et al. Considering renal risk while managing cancer. Cancer Manage Res 2017;9:167–178. DOI: 10.2147/CMAR.S125864.
  18. Koene RJ, Prizment AE, Blaes A, et al. Shared risk factors in cardiovascular disease and cancer. Circulation 2016;133(11):1104–1114. DOI: 10.1161/CIRCULATIONAHA.115.020406.
  19. Winter MC, Potter VA, Woll PJ. Raised serum urea predicts for early death in small cell lung cancer. Clin Oncol 2008;20(10):745–750. DOI: 10.1016/j.clon.2008.09.001.
  20. Weinstein SJ, Mackrain K, Stolzenberg-Solomon RZ, et al. Serum creatinine and prostate cancer risk in a prospective study. Cancer Epidemiol Biomarkers Prev 2009;18(10):2643–2649. DOI: 10.1158/1055-9965.EPI-09-0322.
  21. Joshi M, Prasad S, Sodhi KS, et al. Implication of serum urea and creatinine estimation in prostate cancer. Int J Recent Trends Science Tech 2014;13:290–292.
  22. Lai SW, Kuo YH, Liao KF. Allopurinol and the risk of prostate cancer. Postgrad Med J 2020;96:102. DOI: 10.1136/postgradmedj-2019- 136862.
  23. Sudha K, Kumarachandra R, Akshatha LN, et al. Evaluation of serum uric acid/inorganic phosphate ratio in prostate disorders and healthy controls. IJBAR 2014;5:345–347. DOI: 10.7439/ijbar.
  24. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 2011;364(19):1844–1854. DOI: 10.1056/NEJMra0904569.
  25. Boyd NS, Quandt Z, Allauddeen N. Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer. Mol Clin Oncol 2017;6(4):589–592. DOI: 10.3892/mco.2017.1186.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.